Ghana To Be Part Of 12 African Countries To Get New Malaria Vaccine. According to the World Health Organization (WHO) and its partners, approximately 18 million doses of the world’s first malaria vaccine, known as Mosquirix, will be distributed to 12 African nations by the year 2025. These countries include Malawi, Ghana, and Kenya, which have already implemented the vaccine through pilot programs.
Due to the overwhelming demand for the vaccine exceeding the available supply, priority will be given to countries with the greatest need and where the maximum impact can be achieved. As a result, Mozambique and Sudan have been excluded from the distribution plan due to their high rates of vaccine drop-outs.
The WHO emphasizes that this vaccine, developed by the British company GSK, has the potential to save one life for every 200 children vaccinated. This is a significant development considering that malaria claims the lives of approximately half a million African children under the age of five each year.
Expanding access to the Mosquirix vaccine is a crucial step in combating the devastating impact of malaria in Africa. By providing vaccinations to the most vulnerable populations, particularly young children, the hope is to significantly reduce the number of malaria-related deaths and improve overall public health in these countries. The successful implementation of the vaccine in Malawi, Ghana, and Kenya during the pilot schemes serves as an encouraging precedent for the upcoming distribution efforts across the continent.
It is important to note that the distribution of the vaccine will be conducted strategically, taking into account the specific needs and circumstances of each country. By targeting regions with the highest malaria burden and the greatest potential for impact, the aim is to maximize the vaccine’s effectiveness in saving lives and reducing the overall malaria-related morbidity and mortality rates.
However, challenges persist in ensuring equitable access to the vaccine, given the limited supply and high demand. The exclusion of Mozambique and Sudan due to their vaccine drop-out rates underscores the importance of not only providing the vaccine but also ensuring its successful administration and completion of the recommended doses.
The introduction of the Mosquirix vaccine marks a significant milestone in the global fight against malaria, particularly in the African context where the burden of the disease is most severe. It offers hope for reducing the alarming number of child deaths caused by malaria and contributes to the broader goal of eradicating this deadly disease. Continued collaboration between organizations such as the WHO, GSK, and their partners will be crucial in expanding access to the vaccine, improving health systems, and ultimately saving countless lives across the African continent.
Source;
Social Plugin